Relatlimab plus nivolumab shows ‘consistent PFS benefit’ in advanced melanoma

Relatlimab plus nivolumab continued to demonstrate a PFS benefit compared with nivolumab alone for patients with previously untreated metastatic or unresectable melanoma, according to a study presented during an ASCO Plenary Series session.
The latest results of RELATIVITY-047, a global, randomized, double-blind phase 2/phase 3 study, appeared consistent with the primary analysis, with no new safety signals, researchers reported.
“Double checkpoint inhibitor therapy works — it is not a redundant strategy,” Georgina V. Long, AO, BSc, PhD, MBBS, FRACP, FAHMS, co-medical director

Relatlimab plus nivolumab continued to demonstrate a PFS benefit compared with nivolumab alone for patients with previously untreated metastatic or unresectable melanoma, according to a study presented during an ASCO Plenary Series session.
The latest results of RELATIVITY-047, a global, randomized, double-blind phase 2/phase 3 study, appeared consistent with the primary analysis, with no new safety signals, researchers reported.
“Double checkpoint inhibitor therapy works — it is not a redundant strategy,” Georgina V. Long, AO, BSc, PhD, MBBS, FRACP, FAHMS, co-medical director